BlueRock Therapeutics vs ViaCyte
BlueRock Therapeutics
Striving to transform the treatment of disease by harnessing the power of cell therapy
478 employees · est. 2016 · Cambridge, United States
ViaCyte
Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes
35 employees · est. 1999 · San Diego, United States
ViaCyte is the older company (2016 vs 1999); BlueRock Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | BlueRock Therapeutics | ViaCyte |
|---|---|---|
| Founded | ||
| Founded | 2016 | 1999 older |
| Headquarters | ||
| Headquarters | Cambridge, United States | San Diego, United States |
| Employees | ||
| Employees | 478 larger | 35 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Acquired | Series D |
| Total Funding | ||
| Total Funding | $1.23B | $235.55M |
| Funding Rounds | ||
| Funding Rounds | 2 | 15 |
| Services | ||
| Services | Development of Cell Therapies, Clinical Trial Management, Research and Development | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with Degenerative Diseases, Healthcare Providers, Medical Researchers | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Cell TherapyClinical Stage BiotechNeurological DiseasesOphthalmic DiseasesParkinson’s DiseasePhotoreceptor Diseases +9 | Regenerative MedicineCell TherapyDiabetes TreatmentStem Cell TherapyPancreatic Islet Progenitor CellsType 1 Diabetes +9 |
| Website | ||
| Website | bluerocktx.com | viacyte.com |
About BlueRock Therapeutics
BlueRock Therapeutics is a cutting-edge, clinical-stage cell therapy company dedicated to reshaping the landscape of disease treatment. Emphasizing the transformative potential of cell therapy, it has constructed a promising pipeline targeting severe neurological and ophthalmic conditions. Key clini...
About ViaCyte
ViaCyte is a biotechnology startup from the United States, focused on developing revolutionary cell replacement therapies for long-term diabetes treatment, aiming to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates a...
Also comparing in this category
Comparing more than these two?
Get BlueRock Therapeutics, ViaCyte and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does BlueRock Therapeutics compare?
A PDF of BlueRock Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Frequently Asked Questions
Compare BlueRock Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at BlueRock Therapeutics on 9 Jun 2026, and ViaCyte on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
